Macías A, Cordero A, García Bolao I
Unidad de Arritmias, Departamento de Cardiología y Cirugía Cardiovascular, Clínica Universitaria, Facultad de Medicina, Universidad de Navarra, Pamplona.
Rev Med Univ Navarra. 2005 Jul-Sep;49(3):48-52.
The era of catheter ablation for the treatment of arrhythmias began in 1981 when Dr Scheinman performed the first atrioventricular junction ablation using direct current shocks in a patient with drug refractory atrial fibrillation and an uncontrolled ventricular rate. With the progress of radiofrequency catheter ablation, the range of arrhythmias amenable to catheter ablation and the number of patients that could be treated safely by this procedure expanded enormously. Lastly, although still in an evolutionary phase, catheter ablation to eliminate atrial fibrillation has been demostrated in the past years to be feasible and clinically useful. On the other hand, innovations in technology and pharmacology, and better preventive and diagnostic tools, have provided our patients with an important improvement in their prognosis. The new developments in molecular genetics and biology are likely to change the way we approach a cardiac patient in the future. The diseases are now being deciphered at the most basic level, and the information obtained opens new possibilities not only for better therapeutic and diagnostic measures but also for prevention of the disease.
心律失常导管消融治疗的时代始于1981年，当时Scheinman医生对一名药物难治性心房颤动且心室率控制不佳的患者首次使用直流电电击进行房室结消融。随着射频导管消融技术的进步，适合导管消融治疗的心律失常范围以及能够通过该手术安全治疗的患者数量大幅增加。最后，尽管仍处于发展阶段，但过去几年已证明消除心房颤动的导管消融是可行的且具有临床实用性。另一方面，技术和药理学的创新以及更好的预防和诊断工具，为我们的患者带来了预后的重要改善。分子遗传学和生物学的新发展可能会改变我们未来治疗心脏病患者的方式。现在这些疾病正在最基本的层面上被破解，所获得的信息不仅为更好的治疗和诊断措施，也为疾病的预防开辟了新的可能性。
